Review of 24-hour linezolid administration

Study and comparison of the pharmacokinetics of continuous infusion of linezolid versus intermittent dosing in patients with renal failure

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251202068186N1

Enrollment

Registered

2026-02-17

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the pharmacokinetics of continuous infusion of linezolid versus intermittent dosing in patients with renal failure. Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention 1: Intervention group: Receiving the Linezolid from Shahid Ghazi Company as a 24-hour continuous infusion at a rate of 50 mg per hour and a loading dose of 600 mg over one hour. Intervent

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years old Fever greater than 37.8°C Informed consent Leukocytosis above 10,000 cells per cubic millimeter Serum lactate above 18 milligram per decilitre Suspected or proven gram-positive infection for which the treating physician has prescribed intravenous linezolid Glomerular filtration rate less than 40 milliliter per minute

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Patients undergoing hemoperfusion and plasmapheresis Dialysis Hypersensitivity to linezolid or any of the product's excipients • Taking any compound that inhibits the enzyme mono-amine oxidase A or B Hematological diseases disseminated intravascular coagulation

Design outcomes

Primary

Measure	Time frame
Percentage of time when the plasma concentration of the drug is above the Minimum Inhibitory Concentration patients. Timepoint: Samples were measured at times before starting the drug (time zero), 1.5, 2, 4, 8, 12, 5.13, 24, 5.25, 36 and 48 hours after starting linezolid. Method of measurement: High Performance Liquid Chromatography Device.;Area under the concentration-time curve. Timepoint: End of sampling. Method of measurement: Concentration-time curve.	—

Measure

Time frame

Percentage of time when the plasma concentration of the drug is above the Minimum Inhibitory Concentration patients. Timepoint: Samples were measured at times before starting the drug (time zero), 1.5, 2, 4, 8, 12, 5.13, 24, 5.25, 36 and 48 hours after starting linezolid. Method of measurement: High Performance Liquid Chromatography Device.;Area under the concentration-time curve. Timepoint: End of sampling. Method of measurement: Concentration-time curve.

—

Secondary

Measure	Time frame
Blood platelet level??. Timepoint: At the beginning of the study and at the end of the study. Method of measurement: Number per microliter of blood.;Albumin to lactate ratio. Timepoint: The beginning and end of the study. Method of measurement: Blood albumin and lactate levels.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Mojtahedzadeh

Tehran University of Medical Sciences

mojtahed@sina.tums.ac.ir+98 21 6634 6239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026